Belovezhdov N, Robeva R
Vutr Boles. 1982;21(3):49-53.
A controlled therapeutic study was carried out on 38 patients with IgA glomerulonephritis. According to the data from the light microscopy, 15 patients were with minimum histological deviations, 21 patients--with focal-segmental glomerulonephritis, and 2 patients--with diffuse. The patients with the minimum histological deviations and focal-segmental glomerulonephritis were grouped into three groups. The first group of 13 patients was treated with indomethacin, 75 mg daily in the course of 8.5 months on the average (6-13 months). The second group of 5 patients was treated with levamisole--3 days with 150 mg daily--two times a month, in the course of 14 months on the average (6.5-30 months). The control group, without any treatment, covered 13 patients. There were no discrepancies in the clinical manifestations, laboratory data and renal function among the patients from the three groups. In an additional group of 7 patients with focal-segmental and diffuse mesangioproliferative glomerulonephritis, five of them with renal insufficiency, a combined immuno-suppressive and anticoagulant treatment with azathioprin, heparin and acenocoumarol was carried out in the course of 15 months on the average (6-35 months). Indomethacin and levamisole treatment had no effect on the clinical manifestations and evolution of the disease. The combined immuno-suppressive and anticoagulant treatment had also no effect on the progress in the terminal renal insufficiency.
对38例IgA肾小球肾炎患者进行了对照治疗研究。根据光镜检查数据，15例患者组织学偏差最小，21例患者为局灶节段性肾小球肾炎，2例患者为弥漫性病变。将组织学偏差最小和局灶节段性肾小球肾炎患者分为三组。第一组13例患者接受吲哚美辛治疗，平均疗程8.5个月（6 - 13个月），每日75毫克。第二组5例患者接受左旋咪唑治疗，每月两次，每次150毫克，连服3天，平均疗程14个月（6.5 - 30个月）。未接受任何治疗的对照组有13例患者。三组患者在临床表现、实验室数据和肾功能方面无差异。在另一组7例局灶节段性和弥漫性系膜增生性肾小球肾炎患者中，其中5例有肾功能不全，平均疗程15个月（6 - 35个月），采用硫唑嘌呤、肝素和醋硝香豆素联合免疫抑制和抗凝治疗。吲哚美辛和左旋咪唑治疗对疾病的临床表现和进展无影响。联合免疫抑制和抗凝治疗对终末期肾功能不全的进展也无影响。
